NSCLCPhase 2NCT02179567
Docetaxel Plus Bevacizumab for Elderly Patients With Stage IV NSCLC
A Phase 2 study testing Docetaxel and Bevacizumab in people with NSCLC, run by Hellenic Oncology Research Group at 5 sites in Greece.
Trial summary
The investigators propose to study the efficacy and safety of the combination of Docetaxel plus Bevacizumab in a Phase II trial of elderly subjects with non-small cell lung cancer Read more about this study
- Who is it for?
- Ages 70 years and older
- Conditions the study is for
- NSCLC
- What is being tested?
- Docetaxel and Bevacizumab
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 26 participants
- Where
- 5 sitesGreece
- Study dates
- Mar 2010to Mar 2013
- Phase
- Phase 2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 70 years and older
- All sexes
- No healthy volunteers
- Older adult
Who may be able to join
- Age ≥70 years old
- Cytologically or histologically documented NSCLC
- Measurable disease according to Response Evaluation Criteria in Solid Tumors (at least one measurable lesion)
- World Health Organisation (WHO) performance status 0-2
- Non-frail patients according to Comprehensive Geriatric Assessment
- No prior chemotherapy
Show all 13Show fewer
- Life expectancy of at least 12 weeks
- Serum bilirubin less than 1.5 times the upper normal limit
- Aspartate Aminotransferase and Alanine Aminotransferase less than 2.5 times the upper normal limit in the absence of demonstrable liver metastases, or less than 5 times the upper normal limit in the presence of liver metastases
- Serum creatinine less than 1.5 times the upper normal limit and Creatinine Clearance >60 ml/min
- Neutrophil count more than 1.5x 109 /L
- Platelet count more than 100x 109 /L
- Before patient enrollment, written informed consent must be given according to Good Clinical Practice guidelines and national/local regulations.
Who cannot join
- Hemoptysis
- Central nervous system metastases
- Hemorrhagic diathesis or coagulopathy
- Anticoagulation therapy; regular use of aspirin (>325 mg/d), nonsteroidal anti-inflammatory agents, or other agents known to inhibit platelet function
- Major surgery within 28 days before enrolment
- Clinically significant cardiovascular disease
Show all 10Show fewer
- Medically uncontrolled hypertension
- Radiological evidence of tumors invading or abutting major blood vessels
- Other co-existing malignancies or malignancies diagnosed within the last 5 years (with the exception of basal cell carcinoma or cervical cancer in situ)
- Any evidence of severe uncontrolled concomitant disease (in the opinion of the investigator)
Trial locations and contacts
5 sites in 1 country.
5 sites in 1 country
Greece5 sites
"Laikon" General Hospital, Medical Oncology Unit, Propedeutic Dep of Internal Medicine
Athens
401 Military Hospital of Athens
Athens
Air Forces Military Hospital of Athens Athens, Greece
Athens
Medical Oncology Unit NIMTS (Veterans Hospital)
Athens
University Hospital of Crete, Dep of Medical Oncology Heraklion, Greece
Heraklion, Crete
About this study
Official title: First Line Treatment of Elderly Patients With Advanced or Metastatic NSCLC With Docetaxel and Bevacizumab
The investigators propose to study the efficacy and safety of the combination of Docetaxel plus Bevacizumab in a Phase II trial of elderly subjects with non-small cell lung cancer
Read the detailed description
About 50% of newly diagnosed cases of NSCLC concern patients older than 65 years, while 30-40% of cases are diagnosed in patients older than 70 years. Furthermore, recent data suggest that during the last decade, the incidence and mortality of NSCLC has decreased in younger patients, while it has increased among older patients. Based on these observations, it becomes clear that NSCLC represents a significant health problem in elderly patients. However, elderly patients are frequently underrepresented in clinical trials evaluating new treatments in NSCLC. Indeed, more than 75% of patients older than 65 years with metastatic NSCLC never receive any kind of chemotherapy in the daily clinical practice.
According to retrospective data,the addition of bevacizumab to a standard, platinum-based chemotherapy regimen improves overall survival in patients with advanced non-squamous-cell, non-small-cell lung cancer and a good ECOG performance status. In addition, bevacizumab prolongs progression-free survival and improves response rate.
In elderly patients there is a complete lack of prospective data regarding the role of bevacizumab. It is not clear whether elderly patients gain any survival benefit or not and if the addition of bevacizumab to standard chemotherapeutic regimens results in a significant increase in toxicity.
There is a clear need to prospectively evaluate the tolerability of bevacizumab when added to standard first-line chemotherapy of elderly NSCLC patients. Therefore, the investigators propose to study the efficacy in elderly (>70 years) patients treated with cytotoxic chemotherapy in combination with bevacizumab in the context of 1st line treatment.
- Conditions
- NSCLC
- Being tested
- Docetaxel, Bevacizumab
- Keywords
- Metastatic NSCLC, Elderly, 1st Line, Bevacizumab-based treatment
- Medical subject headings
- Carcinoma, Non-Small-Cell Lung
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
DocetaxelDrug
Docetaxel: 60mg/m2 i.v on day 1. Cycle repeated ever 3 weeks
BevacizumabDrug
Bevacizumab: 7.5 mg/kg, iv on day 1. Cycle repeated every 3 weeks
| Study group | Role | What they receive |
|---|---|---|
| Doc/Bev | Experimental | Docetaxel/Bevacizumab Receives: Drug: Docetaxel; Drug: Bevacizumab |
What is being measured
The primary outcome is the main question the study is designed to answer.
Overall Response Rate
Measured: Disease evaluation at Week 9
Secondary outcomes (4)
Disease control rate
Disease control rate is defined as the proportion of patients with complete response or partial response or stable disease for at least 16 weeks
Measured: Disease evaluation at Week 9
Progression Free Survival
Measured: 1 year
Overall Survival
Measured: 1 year
Safety Profile
Patients will be evaluated for Adverse Events (related or unrelated to the treatment) on Day 1 of each cycle (cycle repeated every 3 weeks) up to 18 weeks from the date of first dose administration
Measured: Every three weeks up to 18 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Jul 2014 (estimated)
- Study startMar 2010
- Primary completionMar 2013
- Study completionMar 2013
Why it stopped: Terminated due to poor accrual
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for NSCLCStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 26 participants (actual)
Sponsor and investigators
- Lead sponsor
- Hellenic Oncology Research Group
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Lambros Vamvakas, MD, Principal investigator, University Hospital of HerklionAthanasios Karambeazis, MD, Principal investigator, Medical Oncology Unit NIMTS (Veterans Hospital)
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02179567
- Sponsor's protocol ID
- CT/10.03
- Status last verified
- Sep 2015
- First submitted
- 30 Jun 2014
- Last updated
- 28 Sep 2015
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 28 Sep 2015. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- First Line Treatment of Elderly Patients With Advanced or Metastatic NSCLC With Docetaxel and Bevacizumab
- ClinicalTrials.gov ID
- NCT02179567
- Acronym / sponsor ID
- CT/10.03
- Conditions
- NSCLC
- Keywords
- Metastatic NSCLC, Elderly, 1st Line, Bevacizumab-based treatment
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- TerminatedReason stopped: Terminated due to poor accrual
- Enrolment
- 26 participants (actual)
- Lead sponsor
- Hellenic Oncology Research GroupUniversity, hospital or other
- Study start
- Mar 2010
- Primary completion
- Mar 2013 (actual)
- Study completion
- Mar 2013 (actual)
- First posted
- 2 Jul 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The investigators propose to study the efficacy and safety of the combination of Docetaxel plus Bevacizumab in a Phase II trial of elderly subjects with non-small cell lung cancer
Detailed description
About 50% of newly diagnosed cases of NSCLC concern patients older than 65 years, while 30-40% of cases are diagnosed in patients older than 70 years. Furthermore, recent data suggest that during the last decade, the incidence and mortality of NSCLC has decreased in younger patients, while it has increased among older patients. Based on these observations, it becomes clear that NSCLC represents a significant health problem in elderly patients. However, elderly patients are frequently underrepresented in clinical trials evaluating new treatments in NSCLC. Indeed, more than 75% of patients older than 65 years with metastatic NSCLC never receive any kind of chemotherapy in the daily clinical practice.
According to retrospective data,the addition of bevacizumab to a standard, platinum-based chemotherapy regimen improves overall survival in patients with advanced non-squamous-cell, non-small-cell lung cancer and a good ECOG performance status. In addition, bevacizumab prolongs progression-free survival and improves response rate.
In elderly patients there is a complete lack of prospective data regarding the role of bevacizumab. It is not clear whether elderly patients gain any survival benefit or not and if the addition of bevacizumab to standard chemotherapeutic regimens results in a significant increase in toxicity.
There is a clear need to prospectively evaluate the tolerability of bevacizumab when added to standard first-line chemotherapy of elderly NSCLC patients. Therefore, the investigators propose to study the efficacy in elderly (>70 years) patients treated with cytotoxic chemotherapy in combination with bevacizumab in the context of 1st line treatment.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Doc/Bev | Experimental | Drug: Docetaxel, Drug: BevacizumabDocetaxel/Bevacizumab |
Who may qualify
- Ages
- 70 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Older adult
Key inclusion criteria (13 listed)
- Age ≥70 years old
- Cytologically or histologically documented NSCLC
- Measurable disease according to Response Evaluation Criteria in Solid Tumors (at least one measurable lesion)
- World Health Organisation (WHO) performance status 0-2
- Non-frail patients according to Comprehensive Geriatric Assessment
Key exclusion criteria (10 listed)
- Hemoptysis
- Central nervous system metastases
- Hemorrhagic diathesis or coagulopathy
- Anticoagulation therapy; regular use of aspirin (>325 mg/d), nonsteroidal anti-inflammatory agents, or other agents known to inhibit platelet function
- Major surgery within 28 days before enrolment
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| DocetaxelDocetaxel: 60mg/m2 i.v on day 1. Cycle repeated ever 3 weeks | Drug | Doc/Bev |
| BevacizumabBevacizumab: 7.5 mg/kg, iv on day 1. Cycle repeated every 3 weeks | Drug | Doc/Bev |
Primary outcome
Overall Response Rate
Time frame: Disease evaluation at Week 9
4 secondary outcomes
Disease control rate
Time frame: Disease evaluation at Week 9
Progression Free Survival
Time frame: 1 year
Overall Survival
Time frame: 1 year
Safety Profile
Time frame: Every three weeks up to 18 weeks
Results and safety
The study was stopped early (reason given: Terminated due to poor accrual). Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Sep 2015.
Related trials for NSCLC
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingObservational study
A Prospective ,Multicenter ,Non-interventional ,Real-world Study Observing Changes in Molecular Markers Osimertinib Targeted Therapy in EGFRm NSCLC
Non Small Cell Lung Cancer
RecruitingPhase 3
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Non-Small Cell Lung Cancer (NSCLC)
Active, not recruitingPhase 2
Datopotamab Deruxtecan (Dato-DXd, DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer
Metastatic Lung Cancer, Advanced Non Small Cell Lung Cancer
Not yet recruitingPhase 1/2
STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic Carcinoma
NSCLC, Non-Small Cell Lung Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Lambros Vamvakas, MD principal investigator
University Hospital of Herklion
Athanasios Karambeazis, MD principal investigator
Medical Oncology Unit NIMTS (Veterans Hospital)
5 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Docetaxel and Bevacizumab in people with NSCLC, run by Hellenic Oncology Research Group at 5 sites in Greece.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 13 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 28 Sep 2015. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 5 sites in Greece. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study was stopped early (reason given: Terminated due to poor accrual). Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Overall Response Rate (time frame: Disease evaluation at Week 9). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Sep 2015.